[The treatment of keratomycosis with clotrimazole (author's transl)].
Clotrimazole (Bisphenyl-(2-chlorphenyl)-1-imidazolyl-methan) is a recently developed antimycotic with low human toxicity and a broad antifungal spectrum and is well tolerated by the skin and mucosal surfaces. 1% clotrimazole eye ointment was used by the author in the treatment of five corneal ulcers from which fungi could be isolated. Prompt improvement and complete resolution of the ulcer within 3-8 weeks, depending on the severity of the condition at the beginning of the treatment, were achieved in all cases under clotrimazole therapy. The drug in the preparation used was well tolerated and can be recommended as a first choice antimycotic for topical application in the eye.
D000287:Administration, Topical; D000328:Adult; D003022:Clotrimazole / Q000008:administration & dosage / Q000627:therapeutic use*; D003316:Corneal Diseases / Q000188:drug therapy*; D003320:Corneal Ulcer / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*
D007093:Imidazoles; D003022:Clotrimazole
Clotrimazol in der Behandlung von Keratomykosen